Cargando…

Different memory T cell phenotypes are elicited by Ad5 and rare adenoviruses

Detalles Bibliográficos
Autores principales:	Penaloza, P, Borducchi, E, McNally, A, Simmons, N, Teigler, J, Provine, N, Tan, W, Ahmed, R, Barouch, DH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441293/ http://dx.doi.org/10.1186/1742-4690-9-S2-P246

Ejemplares similares

Adenovirus vectors from various serotypes induce distinct cytokine profiles
por: Teigler, JE, et al.
Publicado: (2012)

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

P10-06. Adaptive immune responses elicited by recombinant adenovirus vectors exhibit partial MyD88 dependence
por: Rhee, EG, et al.
Publicado: (2009)

P11-03. Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes
por: Kaufman, DR, et al.
Publicado: (2009)

Development of replication-competent adenovirus based vaccine vectors
por: Abbink, P, et al.
Publicado: (2012)

Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
por: Li, H, et al.
Publicado: (2012)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Transient CD4(+) T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses
por: Provine, Nicholas M., et al.
Publicado: (2016)

P17-13. Hexon hypervariable regions 4–7 contain important Ad5-specific neutralizing antibody epitopes
por: Bradley, RR, et al.
Publicado: (2009)

Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization
por: Penaloza-MacMaster, Pablo, et al.
Publicado: (2016)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies
por: Fuchs, JD, et al.
Publicado: (2012)

Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following SIV challenges of vaccinated monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

P16-09. Adenovirus 5 vector HIV vaccination does not affect mucosal homing markers on Ad5-specific CD4+ T-cells in humans
por: Hutnick, N, et al.
Publicado: (2009)

Humoral immune response profiling with peptide microarrays
por: Reimer, U, et al.
Publicado: (2012)

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
por: Kang, Zi Han, et al.
Publicado: (2018)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
por: Ahmed, T, et al.
Publicado: (2012)

Surviving sepsis in Scotland: is the emergency department ready?
por: Lyon, R, et al.
Publicado: (2008)

Primary brain tumours following breast cancer
por: Hussain, M, et al.
Publicado: (2015)

AKT inhibition mitigates terminal differentiation and preserves central memory phenotype of CD8 T cells
por: Abu Eid, Rasha, et al.
Publicado: (2014)

P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
por: Gabitzsch, ES, et al.
Publicado: (2009)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
por: Provine, Nicholas M., et al.
Publicado: (2022)

Determining the factors affecting breast cancer infectivity by oncolytic adenovirus
por: Mysinger, C, et al.
Publicado: (2005)

Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys
por: Keele, Brandon F., et al.
Publicado: (2017)

Eliciting requirements for a mammography training application
por: Taylor, PM, et al.
Publicado: (2008)

Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses
por: Taipale, Kristian, et al.
Publicado: (2015)

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization
por: Maxfield, Lori F., et al.
Publicado: (2015)

Immunization strategies to elicit mucosal immune response of HIV
por: Shi, Yinghui
Publicado: (2006)

P17-27. Development of recombinant adenovirus 28 vectors for HIV vaccines
por: Ko, S, et al.
Publicado: (2009)

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
por: Havunen, Riikka, et al.
Publicado: (2015)

Full-length HIV-1 immunogens induce greater T lymphocyte responses to conserved epitopes than conserved-region-only HIV-1 immunogens in monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses
por: Hulot, SL, et al.
Publicado: (2012)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
por: Scott, JK, et al.
Publicado: (2012)

Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012)

Optimization and scale-up of cell culture and purification processes for production of an adenovirus-based tuberculosis vaccine
por: Shen, Chun F, et al.
Publicado: (2015)

Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
por: Capasso, Cristian, et al.
Publicado: (2015)

"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours
por: Champion, Brian R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_npnrjt9lgbnroq01bu0octbc1r